TIM3 Expression in Anaplastic-Thyroid-Cancer-Infiltrating Macrophages: An Emerging Immunotherapeutic Target

GEYSELS, ROMINA CELESTE

Biology

MDPI

Lugar: Basel; Año: 2022

naplastic thyroid cancer (ATC) is a highly lethal type of cancer. Patients rarelysurvive beyond 6 months after diagnosis because of its aggressiveness and lack of an effectivetreatment. Therefore, there is an urgent need to identify new biological targets that can be translatedinto novel clinical approaches. Regarding this, ATC is heavily infiltrated with tumor-associatedmacrophages (TAMs), making them attractive therapeutic targets. Immunotherapy is being exploredfor patients with ATC, although its efficacy remains still limited. Hence, we consider that targetingimmune checkpoints in TAMs could be a promising approach for ATC. We have recently shownthat treatment of THP-1 cells (human monocyte-like cell line) with conditioned media derived fromATC cells induced their activation toward a pro-tumoral phenotype along with upregulation of theimmune checkpoint marker TIM3. Experiments using TIM3-blocking antibodies partially reversedthese effects, suggesting the role of this receptor in t